Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"

Rhea-AI Summary

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) announced its common stock began trading on the Nasdaq Capital Market on April 23, 2026 under the ticker LABT. The company is a clinical-stage biotechnology developer of the Bisphosphocin® class and named Nu-3 as its lead product for infected diabetic foot ulcers (iDFU).

Management said it plans to initiate a Phase 2a clinical trial in iDFU shortly and cited the large U.S. diabetes population and concerns about antibiotic-resistant bacterial strains as drivers for development.

Positive

• Shares began trading on Nasdaq under ticker LABT
• Plans to initiate a Phase 2a iDFU trial for lead candidate Nu-3
• Bisphosphocin® class targets broad-spectrum antimicrobial need

Negative

• Company remains clinical-stage with no approved products
• Press release does not disclose financing or cash runway

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SARASOTA, Fla., April 23, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, today announced that shares of the Company's common stock began trading today on the Nasdaq Capital Market ("Nasdaq") under the ticker symbol "LABT".

"We are pleased to announce that Lakewood-Amedex Biotherapeutics' common stock began trading on the Nasdaq Stock Market today," said Doug Manion, M.D., Chairman of the Board. "This listing is a notable achievement marking a new chapter for our company enabling the accelerated development of our Bisphosphocin® class of compounds, including our lead product, Nu-3, as a potential treatment for infected diabetic foot ulcers (iDFU)."

"We plan to initiate a Phase 2a clinical trial in iDFU shortly," stated Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research and Development. "Close to 40 million people in the US live with diabetes, and around one-third will develop a DFU in their life, of which about 50% will be infected at some point. Additionally, numerous patients experience more than one of these events in their life, and antibiotic-resistant bacterial strains are a major concern for the treatment of these patients. We look forward to accelerating our work targeting this major unmet need."

About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

About Nu-3
Nu-3 is Lakewood-Amedex Biotherapeutics Inc.'s lead product being developed for the topical treatment of mildly infected diabetic foot ulcers (iDFU). Nu-3 belongs to a novel class of antimicrobials being developed by Lakewood-Amedex Biotherapeutics Inc. called the Bisphosphocin® class, which possess a unique mechanism of action that enables rapid elimination of a broad spectrum of bacteria, including resistant pathogens and biofilms. Data from initial exploratory clinical trials with Nu-3 using subclinical doses did not reveal any safety signals and showed a trend of positive antimicrobial response and improved wound healing. Based on these results, the company plans to conduct an initial Phase 2a safety and dose response study of Nu-3 followed by a placebo-controlled Phase 2b dose comparative study. This study is also designed to determine the most appropriate administration regimen for Nu-3 gel formation in mildly infected diabetic foot ulcers.

Forward-Looking Statements
This press release may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Generally, the words "believe," "expect," "intsend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. Our Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause our Company's actual results to differ materially from historical experience and our present expectations or projections.

Relying on such statements involves risk, uncertainty and assumptions. These statements  are based on the current estimates and assumptions of the management of Lakewood‐Amedex Biotherapeutics Inc. as of the date of this press release and are subject to uncertainty and changes. All statements obtained in this press release are made only as of the date of this press release and Lakewood‐Amedex Biotherapeutics Inc. does not undertake any obligation to publicly update any forward‐looking statements.

Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-direct-listing-on-nasdaq-shares-trading-under-the-symbol-labt-302751953.html

SOURCE Lakewood-Amedex Biotherapeutics Inc.

FAQ

When did Lakewood-Amedex Biotherapeutics begin trading on Nasdaq under LABT?

The stock began trading on April 23, 2026 on the Nasdaq Capital Market under LABT. According to the company, this marks the start of public trading and a new chapter for its clinical programs.

What is Lakewood-Amedex's lead product Nu-3 targeting and what trial is planned?

Nu-3 is being developed as a treatment for infected diabetic foot ulcers (iDFU). According to the company, it plans to initiate a Phase 2a clinical trial in iDFU shortly to evaluate efficacy and safety.

What is the Bisphosphocin® class that Lakewood-Amedex is developing?

Bisphosphocin® is described as a class of potent, fast-acting, broad-spectrum antimicrobials. According to the company, these compounds are intended to address infections including antibiotic-resistant bacterial strains.

How does the Nasdaq listing affect Lakewood-Amedex shareholders and liquidity?

Listing on Nasdaq provides a public trading venue under LABT, potentially improving liquidity and visibility. According to the company, the listing supports accelerated development of its clinical programs.

Does Lakewood-Amedex disclose financing or cash runway with the Nasdaq listing?

The announcement does not include details on financing or cash runway. According to the company, the release focuses on the Nasdaq listing and planned Phase 2a trial without providing capital-structure specifics.